Evaluation of the analgesic efficacy of AZD1940, a novel cannabinoid agonist, on post-operative pain after lower third molar surgical removal
Jarkko Kalliomäki(AstraZeneca (Sweden)), H. Quiding(AstraZeneca (Sweden)), Peter Annas(Lundbeck (Denmark)), Rolf Karlsten(Uppsala University), Märta Segerdahl, Karin Huizar(AstraZeneca (Sweden)), Annika Reimfelt(AstraZeneca (Sweden)), Lynn R. Webster(Adherent Technologies (United States))
Cited by 59
Related Papers
Predicting Aberrant Behaviors in Opioid-Treated Patients: Preliminary Validation of the Opioid Risk Tool
|Pain Medicine|2005|1.1k
Risk Factors for Opioid-Use Disorder and Overdose
|Anesthesia & Analgesia|2017|504
Discovery and validation of biomarkers to aid the development of safe and effective pain therapeutics: challenges and opportunities
|Nature Reviews Neurology|2020|504
Naloxegol for Opioid-Induced Constipation in Patients with Noncancer Pain
|New England Journal of Medicine|2014|331
Sleep-Disordered Breathing and Chronic Opioid Therapy
|Pain Medicine|2007|309